ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011
Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options.BMC infectious diseases · 2015Pooled it
- Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.Antimicrobial agents and chemotherapy · 2014Trial
- Understanding Recent Developments in Colistin Resistance: Mechanisms, Clinical Implications, and Future Perspectives.Antibiotics (Basel, Switzerland) · 2025Review
- Semi-mechanistic PK/PD modelling of fosfomycin and sulbactam combination against carbapenem-resistantAntimicrobial agents and chemotherapy · 2023Article
- The Relevance and Insights on 1,4-Naphthoquinones as Antimicrobial and Antitumoral Molecules: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Emergence of microbial resistance against nanoparticles: Mechanisms and strategies.Frontiers in microbiology · 2023Review
- Nanomaterials to address the genesis of antibiotic resistance inFrontiers in cellular and infection microbiology · 2022Review
- Ceftolozane/Tazobactam Activity Against Drug-ResistantInfection and drug resistance · 2022Article
- Incidence of Bacterial and Fungal Secondary Infections in COVID-19 Patients Admitted to the ICU.International journal of general medicine · 2022Article
- Light-activated quantum dot potentiation of antibiotics to treat drug-resistant bacterial biofilms.Nanoscale advances · 2021Article
- Article
- Interactions of Tea-Derived Catechin Gallates with Bacterial Pathogens.Molecules (Basel, Switzerland) · 2020Review
- Feasibility of De-Escalation Implementation for Positive Blood Cultures in Patients With Sepsis: A Prospective Cohort Study.Frontiers in pharmacology · 2020Article
- Predictors of Severity and Co-Infection Resistance Profile in COVID-19 Patients: First Report from Upper Egypt.Infection and drug resistance · 2020Article
- Purification and biological activity of natural variants synthesized by tridecaptin M gene cluster and in vitro drug-kinetics of this antibiotic class.Scientific reports · 2019Article
- Characterization of Antigenic Oligosaccharides from Gram-Negative Bacteria via Activated Electron Photodetachment Mass Spectrometry.Analytical chemistry · 2019Article
- Analysis of Risk Factors for Multiantibiotic-Resistant Infections Among Surgical Patients at a Children's Hospital.Microbial drug resistance (Larchmont, N.Y.) · 2019Article
- Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Development and Validation of a Model to Predict Growth of Potentially Antibiotic-Resistant Gram-Negative Bacilli in Critically Ill Children With Suspected Infection.Open forum infectious diseases · 2018Article
- Purification, Characterization andFrontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
The emerging problem of antibiotic resistance, especially among Gram-negative bacteria (GNB), has become a serious threat to global public health. Very few new antibacterial classes with activity against antibiotic-resistant GNB have been brought to market. Renewed and growing attention to the development of novel compounds targeting antibiotic-resistant GNB, as well as a better understanding of strategies aimed at preventing the spread of resistant bacterial strains and preserving the efficacy of existing antibiotic agents, has occurred. The Gram-Negative Resistance Summit convened national opinion leaders for the purpose of analyzing current literature, epidemiologic trends, clinical trial data, therapeutic options, and treatment guidelines related to the management of antibiotic-resistant GNB infections. After an in-depth analysis, the Summit investigators were surveyed with regard to 4 clinical practice statements. The results then were compared with the same survey completed by 138 infectious disease and critical care physicians and are the basis of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.